Additional file 3: of The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease Marc Evans Eirini Palaka Hans Furuland Hayley Bennett Cecilia Linde Lei Qin Phil McEwan Ameet Bakhai 10.6084/m9.figshare.7659851.v1 https://springernature.figshare.com/articles/journal_contribution/Additional_file_3_of_The_value_of_maintaining_normokalaemia_and_enabling_RAASi_therapy_in_chronic_kidney_disease/7659851 Figure S1. Model-estimated cumulative events over five years, according to CKD stage (a–c), RAASi use (d–f) and incidence of hyperkalaemia (g–i). Figure S2. Impact of RAASi cost and efficacy (0–100% of base case values) on discounted lifetime per-patient costs, QALYs, life years and NMB at conventional WTP thresholds. (DOCX 453 kb) 2019-01-31 05:00:00 Chronic kidney disease Potassium, Hyperkalaemia Renin-angiotensin-aldosterone system inhibitor Economic modelling